Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad321 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Isabel Leroux-Roels und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Vaccinology, Ghent University and Ghent University Hospital Ghent, Belgium. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals SA.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
In the previous (parent) study, 2 doses of different formulations of an investigational vaccine against respiratory syncytial virus (RSVPreF3 OA) were well tolerated and immunogenic in older adults. This multicenter phase 2b extension study assessed safety and immunogenicity of a revaccination (third) dose of the 120 μg RSVPreF3-AS01E formulation.
Methods
In total, 122 older adults (60–80 years), previously vaccinated with 2 doses of RSVPreF3-AS01E formulations (containing 30, 60, or 120 μg RSVPreF3 antigen), received an additional 120 μg RSVPreF3-AS01E dose 18 months after dose 2. Vaccine safety was evaluated in all participants up to 6 months and immunogenicity in participants who received 120 μg RSVPreF3-AS01E doses until 1 month after dose 3.
Results
Similar to the parent study, mostly mild-to-moderate solicited adverse events and no vaccine-related serious adverse events or potential immune-mediated disorders were reported. Neutralizing titers and cell-mediated immune responses persisted for 18 months after 2-dose vaccination. Dose 3 increased RSV-specific neutralizing titers against RSV-A and RSV-B and median CD4+ T-cell frequencies. After dose 3, RSV-specific neutralizing titers but not CD4+ T-cell frequencies were below levels detected 1 month after dose 1.
Conclusions
Revaccination with 120 μg RSVPreF3-AS01E 18 months after dose 2 is well tolerated and immunogenic in older adults. Clinical Trials Registration NCT04657198; EudraCT, 2020-000692-21.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Vaccinology, Ghent University and Ghent University Hospital Ghent, Belgium.
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
- Leuven University Vaccinology Centre, Katholieke Universiteit Leuven, Leuven, Belgium.
- GSK, Wavre, Belgium.
- GSK, Rixensart, Belgium.
ORCID-Profile: Marc Van Ranst
Förderung
- GlaxoSmithKline Biologicals SA
Zitieren
APA
Leroux-Roels, I., Van Ranst, M., Vandermeulen, C., Abeele, C. V., De Schrevel, N., Salaun, B., Verheust, C., David, M. P., Kotb, S., & Hulstrøm, V. (2024). Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad321
Vancouver
Leroux-Roels I, Van Ranst M, Vandermeulen C, Abeele CV, De Schrevel N, Salaun B, et al. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad321
BibTeX
@article{LerouxRoels2024,
author = {Leroux-Roels, Isabel and Van Ranst, Marc and Vandermeulen, Corinne and Abeele, Carline Vanden and De Schrevel, Nathalie and Salaun, Bruno and Verheust, Céline and David, Marie-Pierre and Kotb, Shady and Hulstrøm, Veronica},
title = {Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad321}
}
EUVIMED